- Home
- MDGL vs IVZ Comparison
MDGL vs IVZ Comparison
Compare MDGL & IVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDGL | IVZ |
|---|---|---|
| Founded | 2011 | 1935 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 10.3B |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MDGL | IVZ |
|---|---|---|
| Price | $497.82 | $27.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 15 |
| Target Price | ★ $674.45 | $27.43 |
| AVG Volume (30 Days) | 254.7K | ★ 4.9M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.35% |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ 0.51 |
| Revenue | $180,133,000.00 | ★ $5,314,100,000.00 |
| Revenue This Year | $58.39 | N/A |
| Revenue Next Year | $48.55 | $5.83 |
| P/E Ratio | ★ N/A | $54.66 |
| Revenue Growth | N/A | ★ 2.98 |
| 52 Week Low | $265.00 | $14.10 |
| 52 Week High | $615.00 | $29.61 |
Technical Indicators
Market Signals| Indicator | MDGL | IVZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 68.77 |
| Support Level | $461.99 | $22.23 |
| Resistance Level | $502.97 | $29.61 |
| Average True Range (ATR) | 20.67 | 0.79 |
| MACD | -4.06 | 0.22 |
| Stochastic Oscillator | 12.36 | 95.08 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (70% of managed assets) and institutional (30%) clients. At the end of November 2025, the firm had $2.154 trillion in assets under management spread among its equity (62% of AUM), balanced (3%), fixed-income (20%), alternative investment (6%), and money market (9%) operations. Passive products account for close to half of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 31% of its AUM sourced from Europe, Africa, and the Middle East (16%) and Asia (15%).